Biocon Biologics has received approval from the US Food and Drug Administration (FDA) for its diabetes treatment drug, insulin aspart, branded as 'Kirsty'. This regulatory nod has positively impacted Biocon's shares, pushing them to a 52-week high. The approval highlights Biocon's growing presence in the diabetes medication market. Separately, there have been multiple developments in the biosimilars sector, including Fresenius Kabi and Celltrion launching biosimilars for Prolia® and Xgeva® (denosumab), and Bio-Thera submitting a biosimilar application for Simponi® (golimumab). Additionally, Amgen and Accord have settled litigation related to Prolia® and Xgeva®. Other notable industry movements include Harrow entering an agreement to commercialize Samsung Bioepis’s ophthalmology biosimilars, and FuturHealth planning to deliver affordable FDA-approved GLP-1 treatments nationwide.